Literature DB >> 21959058

Hepatocellular necrosis, apoptosis, and proliferation after transcatheter arterial embolization or chemoembolization in a standardized rabbit model.

Yong Wang1, Chuansheng Zheng, Bin Liang, Hui Zhao, Jun Qian, Huimin Liang, Gansheng Feng.   

Abstract

PURPOSE: To evaluate the effect of transcatheter arterial chemoembolization versus transcatheter arterial embolization on hepatocellular damage, apoptosis, proliferation, and proinflammatory response in a rabbit VX2 tumor model.
MATERIALS AND METHODS: Rabbits implanted with VX2 tumors in left liver lobes were randomly divided into three groups: a control group (n = 9) that underwent infusion of distilled water into the left hepatic artery, an embolization group (n = 15) that underwent left hepatic artery embolization with polyvinyl alcohol (PVA) particles, and a chemoembolization group (n = 15) that underwent left hepatic artery infusion of a mixture of 10-hydroxycamptothecin and iodized oil followed by PVA embolization. Serum and liver samples were collected at 6 hours, 3 days, and 7 days postoperatively. Liver damage was measured by liver function tests and histologic analysis. Ki-67 immunohistochemistry and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling were performed to quantify proliferating and apoptotic cells. Serum tumor necrosis factor (TNF)-α levels were measured to assess proinflammatory response.
RESULTS: Compared with embolization, chemoembolization caused liver injury with a greater increase in serum alanine aminotransferase and aspartate aminotransferase levels on days 3 and 7; histologic analysis showed increased hepatic necrosis in adjacent liver tissue beginning at day 3 and increased serum levels of TNF-α at 6 hours. By contrast, chemoembolization resulted in a slower increase in hepatocyte proliferation. Additionally, increased apoptotic hepatocytes were observed after embolization and chemoembolization.
CONCLUSIONS: In contrast to embolization, nonsuperselective transcatheter arterial chemoembolization increased hepatocellular damage and stimulated systemic proinflammatory cytokine release, but inhibited hepatocyte proliferation.
Copyright © 2011 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21959058     DOI: 10.1016/j.jvir.2011.08.005

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  9 in total

1.  Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma.

Authors:  Hana Park; Jae Hyung Jung; Min Kyung Jung; Eui-Cheol Shin; Simon Weonsang Ro; Jeon Han Park; Do Young Kim; Jun Yong Park; Kwang-Hyub Han
Journal:  Hepatol Int       Date:  2020-02-18       Impact factor: 6.047

2.  Therapeutic effects of transarterial infusion of lipiodol and ethanol in various ratios in a rabbit VX2 tumor model.

Authors:  Feng Gao; Ting Qian; Mao Zhen Chen; Hua Bin Yin; Ya Li Xu
Journal:  Diagn Interv Radiol       Date:  2015 May-Jun       Impact factor: 2.630

3.  Imbalance in systemic inflammation and immune response following transarterial chemoembolization potentially increases metastatic risk in huge hepatocellular carcinoma.

Authors:  Tong-Chun Xue; Qing-An Jia; Ning-Ling Ge; Yi Chen; Bo-Heng Zhang; Sheng-Long Ye
Journal:  Tumour Biol       Date:  2015-06-10

4.  Factors affecting the recurrence and survival of hepatocellular carcinoma after hepatectomy: a retrospective study of 601 Chinese patients.

Authors:  T T Zhang; X Q Zhao; Z Liu; Z Y Mao; L Bai
Journal:  Clin Transl Oncol       Date:  2015-11-17       Impact factor: 3.405

5.  The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy.

Authors:  Chaobin He; Yu Zhang; Zhiyuan Cai; Xiaojun Lin
Journal:  Cancer Manag Res       Date:  2019-02-12       Impact factor: 3.989

6.  Intra-arterial EmboCept S® and DC Bead® effectively inhibit tumor growth of colorectal rat liver metastases.

Authors:  Christian Ziemann; Jonas Roller; Markus M Malter; Kira Keller; Otto Kollmar; Matthias Glanemann; Michael D Menger; Jens Sperling
Journal:  BMC Cancer       Date:  2019-10-10       Impact factor: 4.430

7.  Dynamical observation on biological progression of VX2 liver tumors to identify the optimal time for intervention in animal models.

Authors:  Zhenguang Wang; Guangjie Yang; Pei Nie; Junhua Fu; Xufu Wang; Dan Liu
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

8.  Hepatic parenchymal changes following transcatheter embolization and chemoembolization in a rabbit tumor model.

Authors:  Yong Wang; Bin Xiong; Bin Liang; Hui Zhao; Hui Li; Jun Qian; Hui-Min Liang; Gan-Sheng Feng; Chuan-Sheng Zheng
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

9.  Mechanism of action and efficacy of LY2109761, a TGF-β receptor inhibitor, targeting tumor microenvironment in liver cancer after TACE.

Authors:  Xiaojun He; Xiaopeng Guo; Hongsen Zhang; Xiangchuang Kong; Fan Yang; Chuansheng Zheng
Journal:  Oncotarget       Date:  2017-12-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.